Scarica l'app Stockscreener
281.26
2.36%
-6.80
Pre-mercato:
281.71
0.45
+0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$288.06
Aprire:
$283.55
Volume 24 ore:
1.08M
Relative Volume:
0.88
Capitalizzazione di mercato:
$37.55B
Reddito:
$4.29B
Utile/perdita netta:
$577.22M
Rapporto P/E:
66.83
EPS:
4.2086
Flusso di cassa netto:
$641.34M
1 W Prestazione:
-12.54%
1M Prestazione:
-0.56%
6M Prestazione:
-23.33%
1 anno Prestazione:
-10.92%
Intervallo 1D:
$279.43
$286.75
Intervallo di 1 settimana:
$279.41
$380.00
Portata 52W:
$273.11
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
281.26 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
476.31 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.12 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
859.43 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.97 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
ALNY Maintained by B of A Securities -- Price Target Lowered to $410 - GuruFocus
Morgan Stanley Raises its Price Target on Alnylam (ALNY) - Yahoo Finance
BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating - Moomoo
Stifel reiterates Buy rating on Alnylam stock amid trial debate By Investing.com - Investing.com Canada
BofA cuts Alnylam stock price target on conservative outlook By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock - ChartMill
Alnylam Pharmaceuticals Price Target Raised to $485.00/Share From $470.00 by HC Wainwright & Co. - Moomoo
ALNY Maintains Rating by Truist Securities -- Price Target Lowered to $410 - GuruFocus
ALNY Maintained by HC Wainwright & Co. -- Price Target Raised to $485 - GuruFocus
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions - MarketBeat
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $485 - Moomoo
Truist cuts Alnylam stock price target to $410 on ATTR outlook - Investing.com Canada
Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure - Sahm
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) After Rival ATTR-CM Setback And New Partnerships - simplywall.st
Truist Financial Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating - Moomoo
Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/Ionis - MSN
Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations? - Yahoo Finance
AstraZeneca's $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw - finance.biggo.com
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up - 24/7 Wall St.
Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)? - Yahoo Finance
3 Healthcare Stocks Investors Are Turning To As Growth Valuations Look Stretched - Sahm
Alnylam (ALNY) Gets An Opening In ATTR CM As Rival Trial Fails - Yahoo Finance
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $400 to $468 - Moomoo
Alnylam Pharmaceuticals (ALNY) Stock Looks Rich On Earnings Yet Strong On Returns - Yahoo Finance
Alnylam Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $446.43, Implies 38% Upside - TradingView
BridgeBio hits 52-week high on late-stage trial setback for Astra/ Ionis (update) - Seeking Alpha
Alnylam, BridgeBio Gain From AstraZeneca-Ionis Drug Missing Target -- Market Talk - Moomoo
AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction - Barron's
Raymond James Adjusts Price Target on Alnylam Pharmaceuticals to $468 From $420, Maintains Outperform Rating - Moomoo
Stifel maintains Alnylam Pharmaceuticals (ALNY) buy recommendation - MSN
Alnylam jumps as rival ATTR-CM setback appears to strengthen Amvuttra outlook - Quiver Quantitative
Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook - Seeking Alpha
Why is Alnylam Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
ALNY Stock Rallies As RNAi Expansion And AI Deals Deepen - StocksToTrade
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study - Yahoo Finance
Thursday's Stock Market Winners and Losers: Alnylam Pharmaceuticals (ALNY) Jumps 18% as AstraZeneca (AZN) Plunges - Blockonomi
Alnylam Pharmaceuticals focuses on RNAi pipeline as Nasdaq-listed biotech advances rare disease port - AD HOC NEWS
BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) Surge After As - GuruFocus
AstraZeneca, Ionis drug fails big heart disease study in major setback - BioPharma Dive
S&P 500 Futures Climb in Premarket Trading; Alnylam Pharmaceuticals, BridgeBio Pharma Lead - Barron's
Alnylam, BridgeBio shares surge as rival’s heart drug fails late-stage trial - Investing.com Nigeria
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth? - The Globe and Mail
Alnylam Pharmaceuticals (ALNY) Investor Outlook: Exploring a 39% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
ALNYAlnylam Pharmaceuticals Inc Volatility & Greeks - Finviz
Price to book forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Enterprise value to revenue forward of Alnylam Pharmaceuticals, Inc – XETR:DUL - TradingView
Alnylam Pharmaceuticals (NASDAQ:ALNY): An Affordable Growth Stock with Explosive Momentum and a Reasonable Price - ChartMill
What Offers Alnylam Pharmaceuticals (ALNY) Sustained Long-Term Growth? - Insider Monkey
Alnylam (ALNY) Has an RNAi Platform and TTR Franchise Bigger Than a One-Drug Biotech Label - AlphaStreet
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. - Yahoo Finance
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.55%
1.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):